Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. (GLUE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · GLUE · as of Sep 30, 2025
Ownership Breakdown
134
Institutional Holders
▲ 16 vs Q2
$445.21M
Total Inst. Value
▲ $164.64M vs Q2
65.12M
Shares Outstanding
freeFloat 64.71%
60.04M
13F Shares Held
▼ 2.17M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
GLUE largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
NEA MANAGEMENT COMPANY, LLC biological products, (no diagnostic substances) | 7.69M | 9.36% | 9.36% | $57.00B | Nov 14, 2025 | — held |
BVF INC/IL biological products, (no diagnostic substances) | 5.66M | 6.89% | 6.89% | $41.94B | Nov 14, 2025 | — held |
VERSANT VENTURE MANAGEMENT, LLC biological products, (no diagnostic substances) | 5.65M | 6.88% | 6.88% | $41.89B | Nov 10, 2025 | — held |
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 4.92M | 5.98% | 5.98% | $36.43B | Nov 14, 2025 | — held |
PRICE T ROWE ASSOCIATES INC /MD/ biological products, (no diagnostic substances) | 4.64M | 5.64% | 5.64% | $34.36B | Nov 14, 2025 | ▼ 1.69M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 3.82M | 4.64% | 4.64% | $28.27B | Nov 12, 2025 | ▼ 31.3K |
SUVRETTA CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 3.36M | 4.09% | 4.09% | $24.90B | Nov 14, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.99M | 3.64% | 3.64% | $22.15B | Nov 7, 2025 | ▼ 151.6K |
FMR LLC biological products, (no diagnostic substances) | 2.81M | 3.42% | 3.42% | $20.84B | Nov 13, 2025 | ▲ 524.2K |
AISLING CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 1.47M | 1.79% | 1.79% | $10.91B | Nov 12, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
14
Increased
+2.25M shares11
New Positions
first time holders15
Decreased
−3.40M shares0
Sold Out
fully exitedNet shares change (top 50)
1.14M
+2.25M / −3.40M
Net new holders
+10
11 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
GLUE insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
13
Sell transactions
0.46
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Warmuth Markus President & CEO | Jun 1, 2026 | Sale | 4,998 | $19.41 | $97.0K | 595.0K | Form 4 ↗ |
Warmuth Markus President & CEO | Jun 1, 2026 | Sale | 468 | $19.73 | $9.2K | 594.5K | Form 4 ↗ |
Townson Sharon Chief Scientific Officer | May 29, 2026 | Sale | 6,000 | $19.87 | $119.2K | 67.8K | Form 4 ↗ |
Champoux Jennifer Chief Operating Officer | May 27, 2026 | Sale | 2,175 | $20.00 | $43.5K | 62.4K | Form 4 ↗ |
Champoux Jennifer Chief Operating Officer | May 22, 2026 | Sale | 2,176 | $19.00 | $41.3K | 62.4K | Form 4 ↗ |
Manning Anthony M. director | May 21, 2026 | Sale | 10,000 | $18.01 | $180.1K | 0 | Form 4 ↗ |
Warmuth Markus President & CEO | May 1, 2026 | Sale | 5,467 | $18.92 | $103.4K | 600.0K | Form 4 ↗ |
Warmuth Markus President & CEO | Apr 14, 2026 | Sale | 8,000 | $17.64 | $141.1K | 605.5K | Form 4 ↗ |
Nickson Philip Chief Business & Legal Officer | Apr 9, 2026 | Sale | 5,845 | $17.69 | $103.4K | 55.0K | Form 4 ↗ |
Bowen Matthew Principal Accounting Officer | Apr 6, 2026 | Award | 4,300 | — | — | 25.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Monte Rosa Therapeutics, Inc. (GLUE) is primarily owned by institutional investors, who hold approximately 92.2% of total shares outstanding. Company insiders own approximately 35.29%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Monte Rosa Therapeutics, Inc. is NEA MANAGEMENT COMPANY, LLC, holding approximately 7.69 million shares — equal to 9.36% of outstanding shares — as of September 30, 2025.
A total of 134 institutional investors currently hold GLUE stock, with a combined institutional value of approximately $445,210,041 as of the most recent 13F filing period.
Frequently asked questions
GLUE ownershipMonte Rosa Therapeutics, Inc. (GLUE) is primarily owned by institutional investors, who hold approximately 92.2% of shares. The largest shareholder is NEA MANAGEMENT COMPANY, LLC with a 9.36% stake. Company insiders hold 35.29%. Data sourced from SEC Form 13F as of September 30, 2025.